Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Minerva Urologica e Nefrologica 2018 June;70(3) > Minerva Urologica e Nefrologica 2018 June;70(3):340-6



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Urologica e Nefrologica 2018 June;70(3):340-6

DOI: 10.23736/S0393-2249.18.03107-7


lingua: Inglese

Moderate-to-high cardiovascular risk is associated with increased lower urinary tract storage symptoms in patients with benign prostatic enlargement

Cosimo DE NUNZIO 1 , Giovanni TRUSCELLI 2, Fabrizio PRESICCE 1, Mariangela BELLANGINO 1, Mauro GACCI 3, Carlo GAUDIO 2, Andrea TUBARO 1

1 Department of Urology, Ospedale Sant’Andrea, Sapienza University, Rome, Italy; 2 A. Reale Department of Heart and Great Vessels, Umberto I Polyclinic, Sapienza University, Rome, Italy; 3 Department of Urology, Careggi Hospital, University of Florence, Florence, Italy


BACKGROUND: To assess the association between cardiovascular risk (CVR) and lower urinary tract symptoms (LUTS) in men with benign prostatic enlargement (BPE).
METHODS: We enrolled a consecutive series of men with LUTS/BPE. International Prostate Symptom Score (IPSS), voiding (vIPSS) and storage (sIPSS) subscore and prostate volume were evaluated. We defined CVR according to the European Association of Cardiologist Guidelines, and metabolic syndrome (MetS) according to the Adult Treatment Panel III (ATP III).
RESULTS: A total of 509 patients were enrolled. Median age was 66 years (IQR: 60-72), IPSS 9 (IQR: 5-15), vIPSS 5 (IQR: 2-9), sIPSS 4 (IQR: 2-7), Prostate volume was 54 cc (IQR: 40-73). Overall 309/509 (60.7%) patients had a moderate/high CVR and 128/509 presented MetS (25.1%). 297/509 (58.3%) men had an IPSS>7 and 282/509 (55.4%) a sIPSS>3. Men with moderate-to-severe CVR had higher IPSS (9; IQR: 4-14 vs. 10; IQR: 5-16; P=0.01), higher vIPSS (6; IQR: 2-9 vs. 4; IQR: 2-8; P=0.06) and higher sIPSS (4; IQR: 2-8 vs. 3; IQR: 1-6; P=0.005) when compared with no/low CVR patients. On multivariate analysis CVR was associated with an increased risk of IPSS>7 (OR=1.794; 95% CI: 1.111-2.888; P=0.01) and sIPSS>3 (OR=1.593; 95% CI: 1.101-2.555; P=0.04).
CONCLUSIONS: A moderate/high CVR is associated with an increased risk of LUTS, particularly storage LUTS. Although the pathophysiology is yet to be understood, it can be assumed that an increased CVR may be associated with LUTS/BPE presence.

KEY WORDS: Prostatic hyperplasia - Cardiovascular system - Lower urinary tract symptoms - Metabolic syndrome - Prostate

inizio pagina